{"version":"1.0","type":"link","title":"Real-world comparison of treatments with antibodies targeting the CGRP pathway or botulinum toxin type A for resistant migraine.","author_name":"Gardon L 외","author_url":"https://prs-insight.online/author/Gardon%20L","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/51437","thumbnail_width":1200,"thumbnail_height":630}